News

Rexahn has signed an exclusive collaboration and option for license agreement with the Partner Co., for the development of RX-3117. RX-3117 is a small molecule, new chemical entity

Palkion has initiated preclinical development studies for orally available anemia therapeutic candidate, that modulates the Hypoxia-Inducible factor Prolyl Hydroxylase (HIF-PH) enzyme system. CrystalGenomics would use its structure-based drug

Juvaris has signed an agreement with Antigen Discovery (ADi) to access ADi’s high-throughput protein microarray screening system to discover novel disease-specific antigens. Juvaris will sponsor research for multiple

Biovest, a subsidiary of Accentia Biopharmaceuticals, has announced that BiovaxID, a personalized therapeutic anti-cancer vaccine, is available on a named-patient basis in Europe. A named-patient program is a

Takeda Global Research and Development Center has received a complete response letter from FDA, regarding the new drug application (NDA) for alogliptin. Its a selective dipeptidyl peptidase IV

GlaxoSmithKline (GSK) announced that the Commercial Court in Dublin, Ireland, has ruled in patent litigation regarding GSK’s Seretide, an inhaled respiratory treatment for asthma and COPD. Justice Charleton

Galderma’ Azzalure (botulinum toxin Type A), manufactured by Ipsen, has received marketing authorization in from the regulatory authorities in Germany. It is meant for the temporary improvement in

Ortho Clinical Diagnostics (OCD) has opened a new manufacturing facility in Pencoed, Wales. The new, 110,000 square feet facility would employ over 350 people in manufacturing operations, quality,

Aclasta (zoledronic acid 5 mg) has been approved in the European Union (EU) to treat men and postmenopausal women with osteoporosis. It is caused by long-term use of